QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NVS

QT63Novartis AG
NYSE·Healthcare·Drug Manufacturers - General·Switzerland
Latest market price
147.08
-3.80-2.52%
OverviewShort InterestFilings
NVSQT63Novartis AG·NYSE
OverviewShort InterestFilings
147.08-2.52%
TA
Loading chart...
Screen all →
LLY-1.21%$1098.57JNJ-2.48%$228.39ABBV-2.08%$216.63MRK-1.36%$113.87AZN-1.66%$174.93NVO-0.76%$43.19AMGN-1.19%$337.60GILD-1.35%$123.76
Snapshot
Index-P/E21.17EPS (ttm)
6.98
Insider Own-
Shs Outstand2.03B
Perf Week-4.44%
Market Cap285.34BForward P/E15.13EPS next Y9.72Insider Trans-Shs Float-Perf Month-2.23%
Enterprise Value325.58BPEG2.48EPS next Q2.19Inst Own-Short Float-Perf Quarter-0.75%
Income13.47BP/S5.14EPS this Y24.78%Inst Trans-Short Ratio-Perf Half Y8.92%
Sales55.47BP/B7.39EPS next Y11.62%ROA11.34%Short Interest-Perf YTD6.68%
Book/sh19.13P/C15.04EPS next 5Y10.41%ROE31.54%52W High170.47 -13.72%Perf Year26.35%
Cash/sh3.43P/FCF17.16EPS past 3/5Y-ROIC14.89%52W Low112.34 30.92%Perf 3Y-
Dividend Est.4.74 (3.22%)EV/EBITDA14.61Sales past 3/5Y8.04% 1.90%Gross Margin75.13%Volatility1.03% 1.33%Perf 5Y-
Dividend TTM4.74 (3.22%)EV/Sales5.87EPS Y/Y TTM48.04%Oper. Margin29.88%ATR (14)2.81Perf 10Y-
Dividend Ex-DateMar 11, 2026Quick Ratio0.65Sales Y/Y TTM8.37%Profit Margin24.31%RSI (14)45.18Recom2.80
Dividend Gr. 3/5Y6.30% 5.28%Current Ratio0.85EPS Q/Q-12.72%SMA20-1.58%Beta0.41Target Price170.00
Payout61.00%Debt/Eq1.22Sales Q/Q-0.70%SMA50-1.24%Rel Volume1.25Prev Close150.88
Employees75,883LT Debt/Eq0.67EarningsJul 21SMA2003.40%Avg Volume1.49MPrice147.08
IPO DateNov 07, 1996Option/ShortYes / YesEPS/Sales Surpr.-5.69% -2.42%Net Debt/EBITDA1.81Volume1,869,609Change-2.52%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-26-26ReiteratedMorgan StanleyOverweight$143 → $170
Jan-06-26UpgradeBarclaysUnderweight → Equal Weight
Dec-10-25ReiteratedHSBCHold$106 → $112
Dec-08-25UpgradeJP MorganNeutral → Overweight
Dec-03-25ReiteratedMorgan StanleyEqual Weight$136 → $143
Oct-29-25ReiteratedCFRA$108 → $126
Sep-12-25DowngradeGoldman SachsNeutral → Sell
Feb-13-25DowngradeUBSBuy → Neutral
Nov-19-24DowngradeErste GroupBuy → Hold
Oct-30-24ReiteratedBMO CapitalMarket Perform$118 → $120
Latest News
Jun-18-26
Jun-18-2607:54AM
Curium Prevails Patent Dispute Against Novartis Subsidiary Regarding Curium's Lutetium Lu 177 Dotatate Product; Court Claims Advanced Accelerator Applications' Claims Against Curium InvalidBenzinga
Jun-12-26
Jun-12-2608:13AM
Alpha Tau Medical: A Lot Of Shots On GoalSeekingAlpha
Jun-11-26
Jun-11-2606:49PM
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform PotentialSeekingAlpha
09:14AM
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease StudyBenzinga
09:14AM
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease StudyBenzinga
Jun-09-26
Jun-09-2609:59AM
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg ExpansionsSeekingAlpha
09:59AM
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg ExpansionsSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue56,05354,81151,722
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A13,86213,69012,827
Gross Profit42,19141,12238,895
Selling, General and Administrative Excl. Other13,32613,30612,566
Research and Development11,24810,74210,022
Other Operating Expense49701,763
Operating Income17,12117,07414,544
Interest Expense1,2221,1871,036
Unusual Expense
———
Non-Operating Income (Expense)120-561-102
Net Income Before Taxes15,78416,43613,640
Income Taxes2,2702,3971,701
Consolidated Net Income13,53414,05611,941
Net Income From Continuing Operations13,51414,03911,939
Net Income13,53414,05611,941
EPS (Recurring)7.027.255.92
EPS (Basic, Before Extraordinaries)7.027.255.92
EPS (Diluted)6.987.195.87
EBITDA22,40022,98720,715
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio21.0719.18—
Price To Sales Ratio5.014.88—
Gross Margin75.2775.0375.20
Operating Margin30.5431.1528.12
Net Margin24.1525.6423.09
Shares Outstanding1,9091,9392,018
Market Capitalization280,776267,330—
Operating Lease Expense
———
Insider Trading Volume
$161.74$149.28$136.82$124.36$111.90● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR